Dare Bioscience, Inc. (DARE)

NASDAQ: DARE · IEX Real-Time Price · USD
0.940
-0.010 (-1.03%)
Dec 2, 2022 4:00 PM EST - Market closed
-1.03%
Market Cap 80.58M
Revenue (ttm) 10.00M
Net Income (ttm) -24.55M
Shares Out 84.82M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 113,933
Open 0.95
Previous Close 0.95
Day's Range 0.921 - 0.95
52-Week Range 0.88 - 2.51
Beta 1.21
Analysts Buy
Price Target 4.85 (+415.8%)
Earnings Date Nov 10, 2022

About DARE

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive;... [Read more]

Industry Health Care Equipment & Supplies
Employees 20
Stock Exchange NASDAQ
Ticker Symbol DARE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for DARE stock is "Buy." The 12-month stock price forecast is 4.85, which is an increase of 415.85% from the latest price.

Price Target
$4.85
(415.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 weeks ago - Zacks Investment Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET

3 weeks ago - GlobeNewsWire

Daré Bioscience to Present at the Stifel 2022 Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, ...

3 weeks ago - GlobeNewsWire

Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on Novemb...

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m...

1 month ago - GlobeNewsWire

Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study

Statistically Significant Results for Improvement in both the Vasomotor and the Vaginal Symptoms of Menopause

1 month ago - GlobeNewsWire

Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®...

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive Product Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered,...

1 month ago - GlobeNewsWire

Daré Bioscience to Participate in Two Upcoming Conferences

SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO,...

2 months ago - GlobeNewsWire

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET

3 months ago - GlobeNewsWire

Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on Augus...

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m...

4 months ago - GlobeNewsWire

Daré Bioscience to Participate in Maxim Group Women's Health Panel

SAN DIEGO, July 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will be pa...

4 months ago - GlobeNewsWire

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

Meeting to be reconvened solely with respect to Proposal 5 Meeting to be reconvened solely with respect to Proposal 5

5 months ago - GlobeNewsWire

Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, the company's President and CEO, w...

6 months ago - GlobeNewsWire

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 28.57% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update

Conference Call and Webcast Today at 4:30 p.m. ET

6 months ago - GlobeNewsWire

Daré Bioscience Announces NIH Grant Award

Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception

6 months ago - GlobeNewsWire

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%).  Xaciato is an FDA-approved medication for treating bacterial...

Other symbols: OGN
8 months ago - Benzinga

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

Entered into an exclusive global license agreement with Organon to commercialize XACIATO™  (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective

8 months ago - GlobeNewsWire

Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, ...

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p....

8 months ago - GlobeNewsWire

Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will part...

8 months ago - GlobeNewsWire

Daré Bioscience to Participate in Upcoming Conferences

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive...

9 months ago - GlobeNewsWire

Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

11 months ago - Zacks Investment Research

Daré Bioscience's One-Time Bacterial Vaginosis Treatment Scores FDA Approval

The FDA has approved Daré Bioscience Inc (NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial vaginosis.  Xaciato is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as ...

11 months ago - Benzinga

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of -63.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st...

1 year ago - Zacks Investment Research